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were	 not	 significantly	 different	 in	 G84E	 carriers	 and	 non‐carriers.	 Evaluation	 of	 32	
established	common	risk	alleles	revealed	significant	associations	of	risk	alleles	at	13	 loci,	















One	 possible	 contributor	 to	 high	 Norwegian	 PCa	 mortality	 rates	 is	 an	 ancestry‐
associated	difference	in	the	burden	of	genetic	risk	factors,	 including	variants	which	might	
interact	with	environmental	 factors	 to	 increase	 risk	 and	possibly	disease	aggressiveness.	
Twin	studies	suggest	that	PCa	exhibits	a	high	degree	of	heritability	which	is	more	significant	
than	other	common	cancers	including	breast	and	colon	cancer	(2).	Genome‐wide	association	
studies	(GWAS)	have	 identified	at	 least	100	single‐nucleotide	polymorphism	 loci	or	SNPs	
that	 are	 associated	with	 increased	 risk	 of	 PCa,	 at	 least	 in	men	 of	 European	 descent	 (3).	
Although	the	impact	of	each	individual	risk	SNP	is	small,	men	who	carry	the	top	percentiles	
of	 inherited	 risk	 alleles	 are	 4‐6‐fold	more	 likely	 to	 be	 diagnosed	with	 PCa	 (4,	 5).	 Recent	
studies	suggest	PCa	risk	SNPs	account	 for	~33%	of	 familial	PCa	risk	 in	men	of	European	
ancestry	 (3).	 	 An	 analysis	 of	 PCa	 risk	 SNPs	 in	 the	 Norwegian	 population	 has	 not	 been	
previously	reported	to	our	knowledge.	
	
In	 early	 2012	 the	 identification	 of	 the	 first	 bona	 fide	 prostate	 specific	 cancer	
susceptibility	gene,	HOXB13	was	reported	(6).	This	finding	has	been	confirmed	by	many	labs	
around	the	world	(eg	ref	7)	as	well	as	by	researchers	in	the	International	Consortium	for	
Prostate	 Cancer	 Genetics	 (ICPCG)	 (8).	 Through	 combined	 analyses	 of	 different	 study	
populations	within	the	ICPCG,	the	observation	was	made	that	the	most	common	mutation	in	
HOXB13	in	US	men,	G84E,	was	found	to	be	at	the	highest	frequency	in	individuals	of	Nordic	
descent.	 Indeed,	 as	many	 as	 8	 to	 10%	of	 Swedish	 (9)	 and	 Finnish	 (10)	men	with	 family	
history	positive	prostate	cancer	diagnosed	at	an	early	age	carry	a	G84E	HOXB13	mutation,	
compared	to	~1%	or	less	in	unaffected	men.	A	critical	additional	finding	was	that	all	G84E	










































































SNP	 genotype	 frequencies	 were	 also	 compared	 between	 cases	 with	 high	 grade	
(Gleason	7	or	higher)	and	all	other	study	individuals	(cases	with	Gleason	6	or	less	as	well	as	
all	controls).	As	expected	from	previous	studies	(3),	most	SNPs	were	not	associated	with	high	
grade	disease.	However,	5	SNPs	demonstrated	 increased	 frequencies	 in	high	grade	cases,	
reaching	P	values	of	0.05	or	less.		
	



























identified	 as	 a	 possible	 component	 in	 disease	 progression	 through	 the	 coordination	 of	













of‐function	ATM	mutation.	Together	with	L144P	 and	Y88D	 observed	 in	different	PCa	 cell	
lines	(LNCaP	and	LAPC4	respectively	(6)),	this	brings	the	total	number	of	unique	HOXB13	
mutations	found	to	date	to	14.	Further	study	is	required	to	understand	the	association	(and	
function)	of	the	variant	alleles	with	PCa	risk.	In	the	current	study	we	did	not	find	any	novel	
variants	in	the	Norwegian	population.	
	
This	study	provides	evidence	to	support	the	possible	use	of	PCa	risk	SNPs	to	stratify	
risk	in	the	Norwegian	population.	Indeed,	calculation	of	a	genetic	risk	score	using	the	SNPs	
genotyped	in	this	study	allows	for	the	stratification	of	risk	for	PCa	across	a	5	fold	range,	i.e.	
men	who	are	in	the	upper	10%	of	risk	allele	carriers	are	~5	fold	more	likely	to	be	diagnosed	
with	prostate	cancer	than	men	in	the	lowest	10%.	This	level	of	risk	is	sufficient	to	warrant	
consideration	of	genetic	risk	estimate	calculations	for	targeted	early	screening	in	the	general	
population	(19).	The	use	of	SNPs	to	identify	men	in	the	Norwegian	population	who	are	at	
increased	inherited	risk	for	PCa	and	thus	would	benefit	 from	early	disease	screening	and	
monitoring	could	eventually	result	in	significant	declines	in	mortality	and	morbidity	in	these	
men.		
	
While	both	HOXB13	G84E	and	PCa	risk	SNPs	appear	to	contribute	to	the	inherited	risk	
for	PCa	in	Norway,	these	variants	most	likely	cannot	explain	the	high	rate	of	PCa‐associated	
mortality	in	this	population.	Given	the	recent	findings	of	how	important	deleterious	germline	
mutations	in	BRCA2	and	potentially	other	DNA	repair	genes	are	in	predisposing	men	to	more	
aggressive	PCa,	it	would	be	important	to	examine	the	frequency	of	deleterious	mutations	in	
these	genes	in	this	population.	In	particular,	a	survey	of	the	frequency	of	Norwegian	founder	
mutations	in	high	penetrance	genes	like	BRCA1	(20),	ATM	(21),	PMS2	(22),	and	CHEK2	(23)	
might	provide	some	novel	insight	into	this	question.	
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